Business
Scancell to present at the Calculus Investor Forum
Scancell to present at the Calculus Investor Forum.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0690F Scancell Holdings Plc 16 February 2018 \n\n16 February 2018\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nScancell to present at the Calculus Investor Forum\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that Cliff Holloway, Chief Executive Officer and Lindy Durrant, Chief Scientific Officer, have been invited to present an overview of the Company alongside recognised experts in the fields of melanoma, lung cancer and the development of innovative immunotherapies, at the Calculus Investor Forum in London on Friday 16 February 2018 at 12.15pm GMT.\n \nA PDF of the presentation will be available on the investors section of the Scancell website at the same time and a recording will be available thereafter. There will be no material information presented that is not already in the public domain.\n \n \nFor Further Information: \n \n\n\n\n\nScancell\n\n\n\n\n\n\n\n\n\n\nDr John Chiplin, Chairman\nDr Cliff Holloway, CEO\n\n\nScancell Holdings Plc\n\n\n+1 858 361 6288\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nFreddy Crossley (Corporate Finance)\nTom Salvesen (Corporate Broking)\n\n\nPanmure Gordon & Co\n\n\n+44 (0) 20 7886 2500\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMo Noonan/Simon Conway\n\n\nFTI Consulting\n\n\n+44 (0) 20 3727 1000\n\n\n\n\n \nAbout Scancell \n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. \n \nScancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence. \n \nScancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells. \...